JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. have completed the clinical trial notification process with Japan’s PMDA for the Phase I/II study of JR-446, a treatment for the ultra-rare Sanfilippo syndrome type B (MPS IIIB). This milestone follows their 2023 partnership to commercialize JR-446, which showed promising preclinical results and represents a significant step for both companies in addressing unmet medical needs in ultra-rare diseases.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
